Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:40 UTC |
---|
HMDB ID | HMDB0014565 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Spironolactone |
---|
Description | A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827) |
---|
Structure | [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1 |
---|
Synonyms | Value | Source |
---|
Espironolactona | ChEBI | Spironolactonum | ChEBI | Spironolattone | ChEBI | Aldactone | Kegg | Aldactone a | HMDB | Aquareduct | HMDB | Espironolactona mundogen | HMDB | Frumikal | HMDB | Generosan brand OF spironolactone | HMDB | Merck dura brand OF spironolactone | HMDB | Mundogen brand OF spironolactone | HMDB | Spiro l.u.t. | HMDB | Spirobeta | HMDB | Spironone | HMDB | Wörwag brand OF spironolactone | HMDB | CT-Arzneimittel brand OF spironolactone | HMDB | Duraspiron | HMDB | Ashbourne brand OF spironolactone | HMDB | Azupharma brand OF spironolactone | HMDB | Flumach | HMDB | Pfizer brand OF spironolactone | HMDB | Practon | HMDB | Spirono-isis | HMDB | Betapharm brand OF spironolactone | HMDB | Spiro von CT | HMDB | Alphapharm brand OF spironolactone | HMDB | Alpharma brand OF spironolactone | HMDB | Alter brand OF spironolactone | HMDB | Hormosan brand OF spironolactone | HMDB | Jenaspiron | HMDB | Mayoly-spindler brand OF spironolactone | HMDB | Novo-spiroton | HMDB | Roche brand OF spironolactone | HMDB | Spiractin | HMDB | Spirogamma | HMDB | Spirolactone | HMDB | Spirono isis | HMDB | CT Arzneimittel brand OF spironolactone | HMDB | Cardel brand OF spironolactone | HMDB | Dexo brand OF spironolactone | HMDB | Espironolactona alter | HMDB | Jenapharm brand OF spironolactone | HMDB | Novo spiroton | HMDB | NovoSpiroton | HMDB | Novopharm brand OF spironolactone | HMDB | Pharmafrid brand OF spironolactone | HMDB | Searle brand OF spironolactone | HMDB | Spirolang | HMDB | Spirospare | HMDB | Veroshpiron | HMDB | Verospiron | HMDB | Verospirone | HMDB | Von CT, spiro | HMDB | CT, Spiro von | HMDB |
|
---|
Chemical Formula | C24H32O4S |
---|
Average Molecular Weight | 416.573 |
---|
Monoisotopic Molecular Weight | 416.202130202 |
---|
IUPAC Name | (1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethylspiro[oxolane-2,14'-tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan]-6'-ene-5,5'-dione |
---|
Traditional Name | spironolactone |
---|
CAS Registry Number | 52-01-7 |
---|
SMILES | [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O |
---|
InChI Identifier | InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1 |
---|
InChI Key | LXMSZDCAJNLERA-ZHYRCANASA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as spironolactones and derivatives. These are steroid lactones with a structure based on the spironolactone skeleton. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Steroid lactones |
---|
Direct Parent | Spironolactones and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Spironolactone
- 3-oxo-delta-4-steroid
- 3-oxosteroid
- Oxosteroid
- Delta-4-steroid
- Cyclohexenone
- Gamma butyrolactone
- Tetrahydrofuran
- Carboxylic acid ester
- Carbothioic s-ester
- Cyclic ketone
- Thiocarboxylic acid ester
- Ketone
- Lactone
- Oxacycle
- Carboxylic acid derivative
- Organoheterocyclic compound
- Sulfenyl compound
- Thiocarboxylic acid or derivatives
- Monocarboxylic acid or derivatives
- Organic oxygen compound
- Carbonyl group
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Organosulfur compound
- Aliphatic heteropolycyclic compound
|
---|
Molecular Framework | Aliphatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 134.5 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.002 g/L | Not Available | LogP | 3.4 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Spironolactone,1TMS,isomer #1 | CC(=O)S[C@@H]1CC2=CC(O[Si](C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21 | 3468.4 | Semi standard non polar | 33892256 | Spironolactone,1TMS,isomer #1 | CC(=O)S[C@@H]1CC2=CC(O[Si](C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21 | 3345.4 | Standard non polar | 33892256 | Spironolactone,1TMS,isomer #1 | CC(=O)S[C@@H]1CC2=CC(O[Si](C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21 | 3908.5 | Standard polar | 33892256 | Spironolactone,1TBDMS,isomer #1 | CC(=O)S[C@@H]1CC2=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21 | 3707.4 | Semi standard non polar | 33892256 | Spironolactone,1TBDMS,isomer #1 | CC(=O)S[C@@H]1CC2=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21 | 3576.1 | Standard non polar | 33892256 | Spironolactone,1TBDMS,isomer #1 | CC(=O)S[C@@H]1CC2=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21 | 4035.9 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Spironolactone GC-MS (Non-derivatized) - 70eV, Positive | splash10-0h2u-0109000000-b5dcae38bb499eaabba7 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Spironolactone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Spironolactone GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0006-9836000000-9f600bd39c3b914c0b17 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Spironolactone LC-ESI-ITFT , positive-QTOF | splash10-014i-0000900000-5e2e1944e45fcef225d1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Spironolactone LC-ESI-ITFT , positive-QTOF | splash10-014i-0000900000-406c100eed5b6cdc3286 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Spironolactone 15V, Positive-QTOF | splash10-014i-0000900000-406c100eed5b6cdc3286 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Spironolactone 15V, Positive-QTOF | splash10-014i-0000900000-5e2e1944e45fcef225d1 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 10V, Positive-QTOF | splash10-00or-0009200000-27849e6f24a460d7ac90 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 20V, Positive-QTOF | splash10-05mn-0129000000-5819587c9e746750f5c0 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 40V, Positive-QTOF | splash10-01tl-0192000000-6a35fab760c0aa732723 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 10V, Negative-QTOF | splash10-00xr-0009200000-defcf21ed513948675a3 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 20V, Negative-QTOF | splash10-00di-1009000000-ebe97ba9dd52376b449f | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 40V, Negative-QTOF | splash10-0006-9004000000-2eccefa334bd23b4cdc1 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 10V, Positive-QTOF | splash10-014i-0002900000-f73d8e9df6c71e49d6eb | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 20V, Positive-QTOF | splash10-0uy1-0569200000-db11732abcc12259a54d | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 40V, Positive-QTOF | splash10-0ukc-4593000000-33eba50454259079f605 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 10V, Negative-QTOF | splash10-014i-0001900000-329d630008c4558a5ec5 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 20V, Negative-QTOF | splash10-00xr-7009500000-69af52e904d20a0c7b9b | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Spironolactone 40V, Negative-QTOF | splash10-00di-8009000000-ba8deb5a673f3bd4868e | 2021-09-23 | Wishart Lab | View Spectrum |
|
---|
General References | - Wandelt-Freerksen E: [Aldactone in the treatment of sarcoidosis of the lungs (author's transl)]. Z Erkr Atmungsorgane. 1977 Jul;149(1):156-9. [PubMed:607621 ]
- Berardesca E, Gabba P, Ucci G, Borroni G, Rabbiosi G: Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int J Tissue React. 1988;10(2):115-9. [PubMed:2972662 ]
- Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17. [PubMed:10471456 ]
- Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
- Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
- Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
- Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
- Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
|
---|